Sr. Program Strategy and Operations Director

Enveda reads nature's chemistry with AI - the platform is built on it, and it finds new medicines ~4x faster than the industry standard. We reached unicorn status on a $150M Series D, our first medicines are now in clinical trials with a deep pipeline right behind them, and we're backed by Sanofi, Lux Capital, and Baillie Gifford, with former Pfizer R&D chief Mikael Dolsten on the board.

The role

You'll be the strategic and operational copilot to an Asset Entrepreneur driving one of our molecules, and the connective tissue across a single-threaded asset team. Think of it as the COO of a single-asset biotech, and an Asset Entrepreneur in the making: judged on the speed and quality of the asset's decisions, not on how many meetings you run.

It's a front-row seat to drug development: full exposure across clinical, translational, regulatory, CMC, BD, and the boardroom at a fast-growing startup with a platform the industry doesn't have.